Bellicum Pharma (BLCM) Misses Q4 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Bellicum Pharma (BLCM) Misses Q4 EPS by 19c

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for Fourth Quarter and Year Ended December 31, 2015

March 14, 2016 4:05 PM EDT

BPX-501 clinical data reported at ASH 2015 demonstrated disease-free outcomes in patients with genetic diseases

Three novel product candidates planned to initiate Phase 1 studies in 2016

Management to host conference call and webcast today at 5 p.m. Eastern

HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December 31, 2015, and provided an update on the Company's recent... More